FDA INTERACT Meetings: Early Interactions for Cell and Gene Therapy Sponsors
Camargo
MAY 2, 2021
CMC: Innovative technologies, product manufacturing, reagents, starting materials, critical product components, novel delivery device qualification, and complex software issues. A sponsor must provide concise detail in the meeting package and ask specific , targeted questions so that the FDA can provide meaningful guidance.
Let's personalize your content